<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000046716"><TermName>S-1</TermName><TermDefinition><DefinitionText>A drug that is being studied for its ability to enhance the effectiveness of fluorouracil and prevent gastrointestinal side effects caused by fluorouracil. It belongs to the family of drugs called antimetabolites.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>S-1</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento en estudio por su capacidad de mejorar la eficacia del fluorouracilo y prevenir los efectos secundarios causados por el fluorouracilo en el aparato digestivo. Es un tipo de antimetabolito.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition></GlossaryTerm>
